# A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

Study · id `cardio:ct-nct03657095` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03657095](<https://clinicaltrials.gov/study/NCT03657095>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03657095

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 112 participants.

## Technical summary

Registry record NCT03657095. Non-randomized; no masking; primary purpose treatment. Start 2018-12-10 (actual); primary completion 2019-07-20 (actual). Results posted on 2020-09-07.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 112 participants (enrolled count; ClinicalTrials.gov record NCT03657095, source copy `cardio:ctgov-nct03657095-2020-09-07`, retrieved 2026-10-31)
- Started: 2018-12-10 (actual) (ClinicalTrials.gov record NCT03657095, source copy `cardio:ctgov-nct03657095-2020-09-07`, retrieved 2026-10-31)
- Primary completion: 2019-07-20 (actual) (ClinicalTrials.gov record NCT03657095, source copy `cardio:ctgov-nct03657095-2020-09-07`, retrieved 2026-10-31)
- Completion: 2019-07-20 (actual) (ClinicalTrials.gov record NCT03657095, source copy `cardio:ctgov-nct03657095-2020-09-07`, retrieved 2026-10-31)
- Results first posted: 2020-09-07 (ClinicalTrials.gov record NCT03657095, source copy `cardio:ctgov-nct03657095-2020-09-07`, retrieved 2026-10-31)
- Countries: United States; Israel (ClinicalTrials.gov record NCT03657095, source copy `cardio:ctgov-nct03657095-2020-09-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03657095-2020-09-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
- Acronym: BEAT OLE
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Esuberaprost
- Intervention (Drug): Placebo
- Lead sponsor: Lung Biotechnology PBC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: 5da27e69c82978baf483d25623fb838c983845fb7eaddbe9108d8d57a099129c
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
